Literature DB >> 30107196

Gut microbiota associated with pulmonary tuberculosis and dysbiosis caused by anti-tuberculosis drugs.

Yongfeng Hu1, Qianting Yang2, Bo Liu1, Jie Dong1, Lilian Sun1, Yafang Zhu1, Haoxiang Su1, Jian Yang1, Fan Yang3, Xinchun Chen4, Qi Jin5.   

Abstract

BACKGROUND: An improved understanding of the gut microbiota could lead to better strategies for the diagnosis, therapy and prophylaxis of tuberculosis (TB). The impact of both Mycobacterium tuberculosis (Mtb) infection and anti-TB treatment on the gut microbiota has rarely been studied.
METHODS: We characterized the diversity and composition of the gut microbiota in pulmonary TB patients as well as the effects of anti-TB drugs on the gut microbiota.
RESULTS: Pulmonary Mtb infection led to a minor decrease in the α diversity of the gut microbiota when compared to healthy controls, which mainly resulted from changes in the relative abundance of the members of genus Bacteroides. Anti-TB therapy caused a rapid, significant alteration in the community structure. The relative abundance of members of genus Clostridiales of the phylum Firmicutes significantly decreased during anti-TB treatment, while many members of genus Bacteroides, including Bacteroides OTU230 and Bacteroides fragilis, were among the taxa that increased. OTU8 and OTU2972 assigned to family Erysipelotrichaceae of the phylum Firmicutes showed a dramatic increase 1 week after the start of therapy, while the other members of this family decreased.
CONCLUSIONS: Pulmonary TB and anti-TB treatment caused a distinct dysbiosis of the gut microbiota. Our study contributes valuable information implying potential links between the gut microbiota and TB.
Copyright © 2018 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  16S rRNA; Anti-TB therapy; Gut microbiota; Tuberculosis

Mesh:

Substances:

Year:  2018        PMID: 30107196     DOI: 10.1016/j.jinf.2018.08.006

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  23 in total

1.  The Microbiota of Human Lung of Pulmonary Tuberculosis and the Alteration Caused by Anti-tuberculosis Drugs.

Authors:  Meng Zhang; Li Shen; Xia Zhou; Huidong Chen
Journal:  Curr Microbiol       Date:  2022-09-19       Impact factor: 2.343

2.  Effect of a Novel Hybrid Nanocomposite of Cisplatin-Chitosan on Induced Tissue Injury as a Suggested Drug by Reducing Cisplatin Side Effects.

Authors:  Nagi M El-Shafai; Foad Farrag; Mustafa Shukry; Hany Mehany; Mohamed Aboelmaati; Ola Abu-Ali; Dalia Saleh; Mohamed Ramadan; Ibrahim El-Mehasseb
Journal:  Biol Trace Elem Res       Date:  2021-10-31       Impact factor: 4.081

3.  Compensatory Transition of Bile Acid Metabolism from Fecal Disposition of Secondary Bile Acids to Urinary Excretion of Primary Bile Acids Underlies Rifampicin-Induced Cholestasis in Beagle Dogs.

Authors:  LanLan Gui; QingLiang Wu; YiTing Hu; WuShuang Zeng; XianWen Tan; PingPing Zhu; XueJing Li; Lian Yang; Wei Jia; ChangXiao Liu; Ke Lan
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-22

Review 4.  The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty?

Authors:  Osagie A Eribo; Nelita du Plessis; Mumin Ozturk; Reto Guler; Gerhard Walzl; Novel N Chegou
Journal:  Cell Mol Life Sci       Date:  2019-11-15       Impact factor: 9.261

Review 5.  Unraveling the Interconnection Patterns Across Lung Microbiome, Respiratory Diseases, and COVID-19.

Authors:  Elisavet Stavropoulou; Konstantia Kantartzi; Christina Tsigalou; Theocharis Konstantinidis; Chrissoula Voidarou; Theodoros Konstantinidis; Eugenia Bezirtzoglou
Journal:  Front Cell Infect Microbiol       Date:  2021-01-28       Impact factor: 6.073

6.  Gut microbiome dysbiosis and correlation with blood biomarkers in active-tuberculosis in endemic setting.

Authors:  Aasia Khaliq; Resmi Ravindran; Samia Afzal; Prasant Kumar Jena; Muhammad Waheed Akhtar; Atiqa Ambreen; Yu-Jui Yvonne Wan; Kauser Abdulla Malik; Muhammad Irfan; Imran H Khan
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

Review 7.  Microbiome-immune interactions in tuberculosis.

Authors:  Giorgia Mori; Mark Morrison; Antje Blumenthal
Journal:  PLoS Pathog       Date:  2021-04-15       Impact factor: 6.823

8.  Allogeneic Vγ9Vδ2 T-Cell Therapy Promotes Pulmonary Lesion Repair: An Open-Label, Single-Arm Pilot Study in Patients With Multidrug-Resistant Tuberculosis.

Authors:  Juan Liang; Liang Fu; Man Li; Yuyuan Chen; Yi Wang; Yi Lin; Hailin Zhang; Yan Xu; Linxiu Qin; Juncai Liu; Weiyu Wang; Jianlei Hao; Shuyan Liu; Peize Zhang; Li Lin; Mohammed Alnaggar; Jie Zhou; Lin Zhou; Huixin Guo; Zhaoqin Wang; Lei Liu; Guofang Deng; Guoliang Zhang; Yangzhe Wu; Zhinan Yin
Journal:  Front Immunol       Date:  2021-12-15       Impact factor: 7.561

9.  Longitudinal profiling of gut microbiome among tuberculosis patients under anti-tuberculosis treatment in China: protocol of a prospective cohort study.

Authors:  Wenpei Shi; Yi Hu; Xubin Zheng; Zhu Ning; Meiying Wu; Fan Xia; Stefanie Prast-Nielsen; Yue O O Hu; Biao Xu
Journal:  BMC Pulm Med       Date:  2019-11-11       Impact factor: 3.317

Review 10.  The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases.

Authors:  Dapeng Zhang; Sha Li; Ning Wang; Hor-Yue Tan; Zhimin Zhang; Yibin Feng
Journal:  Front Microbiol       Date:  2020-02-25       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.